For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For survivor Julie Cohen, that search led her to the front lines of medical ...
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, discussed how the standard of care for melanoma is evolving.
The study explores the neoadjuvant approach: administering the immunotherapy drug Keytruda (pembrolizumab) before a surgeon ever picks up a scalpel. Researchers observed dramatic tumor shrinkage and, ...
Survivorship is not the absence of fear. It’s the decision to live anyway. And moving forward, whether into a new home or a new medical chapter, is an act of courage in itself. So here I am, keys in ...
Namodenoson (CF102) demonstrated a favorable safety profile in patients with advanced pancreatic ductal adenocarcinoma (PDAC) in a phase 2a clinical study, meeting the trial’s primary end point and ...
Survivor Julie Cohen discusses her experience with cevostamab, managing CRS side effects, and reaching MRD-negative status through a clinical trial.
Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
March weather becomes a metaphor for survivorship as a mother describes anxiety, relief and uncertainty patients with cancer ...
For Julie Cohen, a diagnosis of multiple myeloma wasn't just a medical hurdle — it was a profound shift in perspective. Initially searching for a cure, she soon realized that navigating a high-risk, ...
The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...
Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results